Trigeminal neuralgia has been described as one of the most painful conditions known to man with a prevalence of approx. 0.2% and few satisfactory treatment options.
Our research group has since 2012 performed innovative research aiming at developing novel treatment options for pain disorders resulting in a wide international scientific network. We have in the past been successful in establishing a start-up and attracting private investments from seasoned, international medical technology investors. Based on this knowledge and knowhow we have developed a new treatment option for trigeminal neuralgia expected to be highly advantageous compared to current treatment options.
The therapy is presumed to have the potential to reduce the burden of pain for an extremely debilitating disorder affecting millions of people world-wide.
Considerable investments are needed to develop the treatment. The main objective of the project was to establish as probable that there is a potential for future revenues supporting the investments needed to develop the treatment. Through market evaluation and price point assessment we showed that the treatment has a significant commercial potential. Our conclusion is that the commercial potential is sufficient to attract funding, public and private, to further development aiming at being able to offer relief to patients with extreme pain.
Det trengs betydelige investeringer for å utvikle behandlingen. Hovedmålet med kvalifikasjonsprosjektet var å utrede om estimerte fremtidige inntekter er høye nok til å utløse investeringene som er nødvendige for å utvikle behandlingen. Gjennom markedsundersøkelser og prispunkt undersøkelser fant vi at behandlingen har et kommersielt potensiale. Vår konklusjon er at det kommersielle potensiale er stort nok til å tiltrekke seg midler nødvendig for å videreutvikle behandlingen med det mål å kunne tilby pasienter med ekstreme smerter et nytt behandlingsalternativ.